BiotechTube
bYoRNA

bYoRNA

Paris, France· Est.
byorna.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $37.4M

Overview

bYoRNA is an early-stage biotech developing a proprietary, cost-effective mRNA bioproduction platform using engineered eukaryotic cells to accumulate and isolate therapeutic mRNA. The company aims to address the scalability and cost challenges of traditional mRNA manufacturing to enable broader therapeutic applications in oncology, infectious diseases, and rare genetic disorders. Founded by seasoned executives with backgrounds in high-tech entrepreneurship and biopharmaceutical development, bYoRNA is positioning itself as a potential enabler for the next generation of RNA therapeutics. Its platform is currently in the pre-clinical/process development stage.

OncologyInfectious DiseasesRare Diseases

Technology Platform

Proprietary eukaryotic cell-based bioproduction platform that accumulates therapeutic mRNA within protective subcellular compartments for high-yield, low-cost production and simplified purification.

Funding History

4
Total raised:$37.4M
Series A$15M
Series A$15M
Seed$4.2M
Seed$3.2M

Opportunities

The global mRNA therapeutics market is expanding rapidly beyond COVID-19 vaccines into oncology and rare diseases, creating massive demand for scalable, low-cost manufacturing.
bYoRNA's disruptive production platform, if validated, could position it as a key enabler for this growth, offering a cost-effective alternative to the industry-standard in vitro transcription method.
Successful development could lead to lucrative partnerships with drug developers or acquisition by a large CDMO or pharmaceutical company.

Risk Factors

The core technology is unproven at commercial scale and must demonstrate it can produce mRNA of equivalent or superior quality to the established, validated standard.
The company faces intense competition from well-funded incumbents scaling the existing IVT process and other next-generation platform startups.
As a pure-play platform company with no proprietary drug candidates, its success is entirely dependent on securing external partnerships, creating significant business development and execution risk.

Competitive Landscape

bYoRNA competes in the mRNA manufacturing technology space, directly challenging the dominant in vitro transcription (IVT) method used by leaders like Moderna, BioNTech, and CureVac, as well as large CDMOs (e.g., Lonza, Catalent). It also faces competition from other next-generation production startups exploring alternative methods (e.g., circular RNA, self-amplifying RNA). Its key differentiator is the use of engineered eukaryotic cells for in vivo mRNA production and accumulation.

More companies in RNA Therapeutics (non-mRNA) →More companies in France →